Development of novel antiviral therapies for hepatitis C virus

Abstract

Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Ago H, Adachi T, Yoshida A, et al. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure, 7: 1417–1426.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Arasappan A, Bennett F, Bogen S L, et al. 2010. Discovery of Narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med Chem Lett, 2-15-2010

  3. 3.

    Bain V G, Kaita K D, Marotta P, et al. 2008. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol, 6: 701–706.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Bartenschlager R, Ahlborn-Laake L, Mous J, et al. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol. 67: 3835–3844.

    PubMed  CAS  Google Scholar 

  5. 5.

    Bartosch B, Dubuisson J, Cosset F L. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med, 197: 633–642.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Bavisotto L, Wang C, Jacobson I, et al. 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  7. 7.

    Bernstein B, Menon R M, Klein C E, et al. 2009. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers. HepDART 2009, Kohala Coast, Hawaii, USA.

  8. 8.

    Blight K J, Kolykhalov A A, Rice C M. 2000. Efficient initiation of HCV RNA replication in cell culture. Science, 290: 1972–1974.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Borawski J, Troke P, Puyang X, et al. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol, 83: 10058–10074.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Borowski P, Deinert J, Schalinski S, et al. 2003. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem, 270: 1645–1653.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Borowski P, Lang M, Haag A, et al. 2007. Tropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase. Antivir Chem Chemother, 18: 103–109.

    PubMed  CAS  Google Scholar 

  12. 12.

    Brainard D M, Anderson M S, Petry A S, et al. 2009. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281in genotype 1 and 3 HCV-infected patients. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  13. 13.

    Bressanelli S, Tomei L, Roussel A, et al. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA, 96: 13034–13039.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Bukh J. 2004. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology, 39: 1469–1475.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Chatterji U, Bobardt M, Lim P, et al. 2010. Cyclophilin A-Independent Recruitment of NS5A and NS5B Into HCV Replication Complexes. J Gen Virol, In press.

  16. 16.

    Chatterji U, Bobardt M, Selvarajah S, et al. 2009. The isomerase active site of cyclophilin A is critical for HCV replication. J Biol Chem, 284: 16998–17005.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Chatterji U, Bobardt M, Selvarajah S, et al. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem, 284: 16998–17005.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Chen C M, He Y, Lu L, et al. 2007. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother, 51: 4290–4296.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Cho N J, Dvory-Sobol H, Lee C, et al. 2010. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Science Translational Medicine, 2: 1–8.

    Article  Google Scholar 

  20. 20.

    Choo Q L, Kuo G, Weiner A J, et al. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359–362.

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Ciesek S, Steinmann E, Wedemeyer H, et al. 2009. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology, 50: 1638–1645.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Clinicaltrials.gov.http://clinicaltrials.gov/.

  23. 23.

    Coelmont L, Kaptein S, Paeshuyse J, et al. 2009. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother, 53: 967–976.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Colonno R. 2010. Discovery and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with broad-spectrum coverage of all HCV genotypes. HCV Drug Discovery, San Diego, CA.

    Google Scholar 

  25. 25.

    Cooper C, Lawitz E J, Ghali P, et al. 2009. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol, 2009; 51(1): 39–46

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Darke P L, Jacobs A R, Waxman L, et al. 1999. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing. J Biol Chem, 274: 34511–34514.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Einav S, Gerber D, Bryson P D, et al. 2008. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol, 26: 1019–1027.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Elazar M, Liu M, McKenna S A, et al. 2009. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology, 137: 1827–1835.

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Erhardt A, Deterding K, Benhamou Y, et al. 2009. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther, 14: 23–32.

    PubMed  CAS  Google Scholar 

  30. 30.

    Evans M J, von H T, Tscherne D M, et al. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 446: 801–805.

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Feldstein A, Kleiner D, Kravetz D, et al. 2009. Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J Clin Gastroenterol, 43: 374–381.

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Fernandes F, Poole D S, Hoover S, et al. 2007. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology, 46: 1026–1033.

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Firbas C, Boehm T, Buerger V, et al. 2010. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine, 28: 2397–2407.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Firbas C, Jilma B, Tauber E, et al. 2006. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine, 24: 4343–4353.

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Flisiak R, Feinman S V, Jablkowski M, et al. 2009. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology, 49: 1460–1468.

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Flisiak R, Feinman S V, Jablkowski M, et al. 2009. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology, 49: 1460–1468.

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Flisiak R, Horban A, Gallay P, et al. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 47: 817–826.

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Forestier N, Reesink H W, Weegink C J, et al. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology, 46: 640–648.

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Fried M, Shiffman M L, Reddy K R, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347: 975–982.

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Gaither L A, Borawski J, Anderson L J, et al. 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology, 397: 43–55.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Gane E J, Oberts S K, Tedman C, et al. 2009. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J Hepatol, 50(Suppl.1): S380 (Abstract 1046).

    Article  Google Scholar 

  42. 42.

    Gane E J, Roberts S K, Stedman C, et al. 2009. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. 44thAnnual Meeting of the European Association for the Study of the Liver. Copenhagen, Denmark.

  43. 43.

    Goto K, Watashi K, Inoue D, et al. 2009. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci, 100: 1943–1950.

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Gozdek A, Zhukov I, Polkowska A, et al. 2008. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother, 52: 393–401.

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Grakoui A, McCourt D W, Wychowski C, et al. 1993. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA, 90: 10583–10587.

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Griffin S, StGelais C, Owsianka A M, et al. 2008. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology, 48: 1779–1790.

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Griffin S D, Beales L P, Clarke D S, et al. 2003. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett, 535: 34–38.

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Habersetzer F, Baumert T F, Stoll-Keller F. 2009. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther, 11: 456–462.

    PubMed  CAS  Google Scholar 

  49. 49.

    Hanoulle X, Badillo A, Wieruszeski J M, et al. 2009. Hepatitis C virus NS5A protein is a substrate for the Peptidyl-Prolyl cis/trans isomerase activity of Cyclophilins A and B. J Biol Chem, 284(20): 13589–13601.

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Heck J A, Meng X, Frick D N. 2009. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem Pharmacol, 77: 1173–1180.

    PubMed  Article  CAS  Google Scholar 

  51. 51.

    Hendricks R T, Fell J B, Blake J F, et al. 2009. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorg Med Chem Lett, 19: 3637–3641.

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Hezode C, Forestier N, Dusheiko G, et al. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med, 360: 1839–1850.

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Hinrichsen H, Benhamou Y, Wedemeyer H, et al. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 127: 1347–1355.

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Hopkins S, Heuman D, Gavis E, et al. 2009. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J Hepatol, 50(Suppl.1): S36 (Abstract 89).

    Article  Google Scholar 

  55. 55.

    Hopkins S, Scorneaux B, Huang Z, et al. 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother, 54: 660–672.

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Horsmans Y, Berg T, Desager J P, et al. 2005. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 42: 724–731.

    PubMed  Article  CAS  Google Scholar 

  57. 57.

    Howe A Y, Cheng H, Johann S, et al. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother, 52: 3327–3338.

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    Hsu M, Zhang J, Flint M, et al. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA, 100: 7271–7276.

    PubMed  Article  CAS  Google Scholar 

  59. 59.

    Jirasko V, Montserret R, Appel N, et al. 2008. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J Biol Chem, 283: 28546–28562.

    PubMed  Article  CAS  Google Scholar 

  60. 60.

    Jones C T, Murray C L, Eastman D K, et al. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol, 81: 8374–8383.

    PubMed  Article  CAS  Google Scholar 

  61. 61.

    Kaita K, Yoshida E, Kunimoto D, et al. 2007. Ph II proof of concept study of celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 non-responder patients. J Hepatol, 46(Suppl. 1): S56 (A127).

    Article  Google Scholar 

  62. 62.

    Kaul A, Stauffer S, Berger C, et al. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog, 5(8): e1000546.

    PubMed  Article  CAS  Google Scholar 

  63. 63.

    Khoury G, Ewart G, Luscombe C, et al. 2010. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother, 54: 835–845.

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Kim J L, Morgenstern K A, Lin C, et al. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 87: 343–355.

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Klade C S, Wedemeyer H, Berg T, et al. 2008. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology, 134: 1385–1395.

    PubMed  Article  CAS  Google Scholar 

  66. 66.

    Korba B E, Montero A B, Farrar K, et al. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res, 77: 56–63.

    PubMed  Article  CAS  Google Scholar 

  67. 67.

    Kwo P, Lawitz E, McCone J, et al. 2009. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J Hepatol, 50(Suppl.1): S4 (Abstract 4).

    Article  Google Scholar 

  68. 68.

    Lalezari J, Asmuth D, Casiro A, et al. 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  69. 69.

    Lamarre D, Anderson P C, Bailey M, et al. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, 426: 186–189.

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Landro J A, Raybuck S A, Luong Y P, et al. 1997. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry, 36: 9340–9348.

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Larrey D, Benhamou Y, Lohse A W, et al. 2010. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol, 50(Suppl.1): S383–S4 (Abstract 1054).

    Google Scholar 

  72. 72.

    Lawitz E, Rouzier R, Nguyen, et al. 2009. Safety and antiviral efficacy of 14 days of the cyclophilin inhibitor NIM811 in combination with pegylated interferon α2A in relapsed genotype 1 HCV infected patients. 44thAnnual Meeting of the European Association for the Study of the Liver. Boston, MA.

  73. 73.

    Lawitz E, Cooper C, Rodriguez-Torres M, et al. 2009. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside hcv polymerase inhibitor in patients with chronic HCV genotype-1 infection. J Hepatol, 50(Suppl.1): S37 (Abstract 92).

    Article  Google Scholar 

  74. 74.

    Lawitz E, Rodriguez-Torres M, DeMicco M, et al. 2009. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol, 50(Suppl.1): S384 (Abstract 1055).

    Article  Google Scholar 

  75. 75.

    Lemm J A, O’Boyle D, Liu M, et al. 2010. Identification of hepatitis C virus NS5A inhibitors. J Virol, 84: 482–491.

    PubMed  Article  CAS  Google Scholar 

  76. 76.

    Lesburg C A, Cable M B, Ferrari E, et al. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol, 6: 937–943.

    PubMed  Article  CAS  Google Scholar 

  77. 77.

    Li Q, Brass A L, Ng A, et al. 2009. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA, 106: 16410–16415.

    PubMed  Article  Google Scholar 

  78. 78.

    Lin K, Perni R B, Kwong A D, et al. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother, 50: 1813–1822.

    PubMed  Article  CAS  Google Scholar 

  79. 79.

    Lin T I, Lenz O, Fanning G, et al. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother, 53: 1377–1385.

    PubMed  Article  CAS  Google Scholar 

  80. 80.

    Lindenbach B D, Evans M J, Syder A J, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science, 309: 623–626.

    PubMed  Article  CAS  Google Scholar 

  81. 81.

    Liu Z, Yang F, Robotham J M, et al. 2009. A Critical Role of Cyclophilin A and its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the HCV Replication Complex. J Virol, doi: JVI.02550-08

  82. 82.

    Liverton N J, Carroll S S, Dimuzio J, et al. 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother, 54: 305–311.

    PubMed  Article  CAS  Google Scholar 

  83. 83.

    Llinas-Brunet M, Bailey M, Fazal G, et al. 1998. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett, 8: 1713–1718.

    PubMed  Article  CAS  Google Scholar 

  84. 84.

    Lohmann V, Korner F, Koch J, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285: 110–113.

    PubMed  Article  CAS  Google Scholar 

  85. 85.

    Love R A, Brodsky O, Hickey M J, et al. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol, 83: 4395–4403.

    PubMed  Article  CAS  Google Scholar 

  86. 86.

    Love R A, Parge H E, Wickersham J A, et al. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell, 87: 331–342.

    PubMed  Article  CAS  Google Scholar 

  87. 87.

    Luik P, Chew C, Aittoniemi J, et al. 2009. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA, 106: 12712–12716.

    PubMed  Article  Google Scholar 

  88. 88.

    Luscombe C A, Huang Z, Murray M G, et al. 2010. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res, doi:S0166-3542 (10) 00341-00344.

  89. 89.

    Ma S, Boerner J E, TiongYip C, et al. 2006. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother, 50: 2976–2982.

    PubMed  Article  CAS  Google Scholar 

  90. 90.

    Malcolm B A, Liu R, Lahser F, et al. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother, 50: 1013–1020.

    PubMed  Article  CAS  Google Scholar 

  91. 91.

    Manns M, Bourliere M, Benhamou Y, et al. 2008. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa 2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype-1 infection. Hepatology, 48(Suppl.1): 1151A (Abstract 882).

    Google Scholar 

  92. 92.

    Manns M, Bourliere M, Benhamou Y, et al. 2008. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R). Hepatology, 48(Suppl.1): 1133A (Abstract 849).

    Google Scholar 

  93. 93.

    Manns M, Muir A, Adda N, et al. 2009. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE 3 study. J Hepatol, 50(Supp.1): S379 (Abstract 1044).

    Article  Google Scholar 

  94. 94.

    Manns M P, McHutchison J G, Gordon S C, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.

    PubMed  Article  CAS  Google Scholar 

  95. 95.

    Mathy J E, Ma S, Compton T, et al. 2008. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother, 52: 3267–3275.

    PubMed  Article  CAS  Google Scholar 

  96. 96.

    McCown M F, Rajyaguru S, Le P S, et al. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother, 52: 1604–1612.

    PubMed  Article  CAS  Google Scholar 

  97. 97.

    McHutchison J G, Everson G T, Gordon S C, et al. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med, 360: 1827–1838.

    PubMed  Article  CAS  Google Scholar 

  98. 98.

    Mercer D F, Schiller D E, Elliott J F, et al. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat.Med, 7: 927–933.

    PubMed  Article  CAS  Google Scholar 

  99. 99.

    Nakagawa M, Sakamoto N, Enomoto N, et al. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun, 313(1), 42–47.

    PubMed  Article  CAS  Google Scholar 

  100. 100.

    Nakagawa M, Sakamoto N, Tanabe Y, et al. 2005. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology, 129: 1031–1041.

    PubMed  Article  CAS  Google Scholar 

  101. 101.

    Nelson D R, Rustgi V, Balan V, et al. 2009. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol, 7: 212–218.

    PubMed  Article  CAS  Google Scholar 

  102. 102.

    Nettles R, Chien C, Chung E, et al. 2008. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology, 48(Suppl.1): 1025A (Abstract LB12).

    Google Scholar 

  103. 103.

    Neumann A U, Lam N P, Dahari H, et al. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.

    PubMed  Article  CAS  Google Scholar 

  104. 104.

    Ng T I, Mo H, Pilot-Matias T, et al. 2007. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology, 45: 1413–1421.

    PubMed  Article  CAS  Google Scholar 

  105. 105.

    Nguyen T T, Gates A T, Gutshall L L, et al. 2003. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother, 47: 3525–3530.

    PubMed  Article  CAS  Google Scholar 

  106. 106.

    Paeshuyse J, Kaul A, De C E, et al. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 43: 761–770.

    PubMed  Article  CAS  Google Scholar 

  107. 107.

    Paeshuyse J, Kaul A, De C E, et al. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 43: 761–770.

    PubMed  Article  CAS  Google Scholar 

  108. 108.

    Pasquinelli C. et al. 2009. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1HCV infection. 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA.

  109. 109.

    Pavlovic D, Neville D C, Argaud O, et al. 2003. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA, 100: 6104–6108.

    PubMed  Article  CAS  Google Scholar 

  110. 110.

    Perni R B, Almquist S J, Byrn R A, et al. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob.Agents Chemother, 50: 899–909.

    PubMed  Article  CAS  Google Scholar 

  111. 111.

    Pierra C, Amador A, Benzaria S, et al. 2006. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem, 49: 6614–6620.

    PubMed  Article  CAS  Google Scholar 

  112. 112.

    Pileri P, Uematsu Y, Campagnoli S, et al. 1998. Binding of hepatitis C virus to CD81. Science, 282: 938–941.

    PubMed  Article  CAS  Google Scholar 

  113. 113.

    Ploss A, Evans M J, Gaysinskaya V A, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 457: 882–886.

    PubMed  Article  CAS  Google Scholar 

  114. 114.

    Pockros P J, Nelson D, Godofsky E, et al. 2008. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology, 48: 385–397.

    PubMed  Article  CAS  Google Scholar 

  115. 115.

    Premkumar A, Wilson L, Ewart G D, et al. 2004. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett, 557: 99–103.

    PubMed  Article  CAS  Google Scholar 

  116. 116.

    Puyang X, Poulin D L, Mathy J E, et al. 2010. Mechanism of Resistance of HCV Replicons to Structurally Distinct Cyclophilin Inhibitors. Antimicrob. Agents Chemother, doi:AAC.01236-09.

  117. 117.

    Randolph J T, Flentge C A, Huang P P, et al. 2009. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors. J Med Chem, 52: 3174–3183.

    PubMed  Article  CAS  Google Scholar 

  118. 118.

    Reesink H W, Fanning G C, Farha K A, et al. 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology, 138: 913–921.

    PubMed  Article  CAS  Google Scholar 

  119. 119.

    Reesink H W, Zeuzem S, Weegink C J, et al. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 131: 997–1002.

    PubMed  Article  CAS  Google Scholar 

  120. 120.

    Reiser M, Hinrichsen H, Benhamou Y, et al. 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41: 832–835.

    PubMed  Article  CAS  Google Scholar 

  121. 121.

    Roberts C D. 2008. Targeting HCV NS4b Function: A New Approach to Anti-HCV Activity. Inaugural HCV Drug Discovery meeting, San Diego, CA.

  122. 122.

    Roberts S K, Cooksley G, Dore G J, et al. 2008. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 48: 398–406.

    PubMed  Article  CAS  Google Scholar 

  123. 123.

    Robida J M, Nelson H B, Liu Z, et al. 2007. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol, 81: 5829–5840.

    PubMed  Article  CAS  Google Scholar 

  124. 124.

    Rodriguez-Torres M, Lalezari J, Gane E J, et al. 2008. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-IFN and ribavirin: subanalysis by race/ethnicity, weight, and HCV genotype. Hepatology, 48(Suppl.1): 1160A (Abstract 899).

    Google Scholar 

  125. 125.

    Rodriguez-Torres M, Lawitz E, Flach S, et al. 2009. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 Day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  126. 126.

    Rodriguez-Torres M, Lawitz E, Conway B, et al. 2010. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naïve genotype 1 HCV-infected patients. 45thAnnual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria

  127. 127.

    Rossignol J F, Kabil S M, El-Gohary Y, et al. 2008. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther, 28: 574–580.

    PubMed  Article  CAS  Google Scholar 

  128. 128.

    Sakai A, Claire M S, Faulk K, et al. 2003. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA, 100: 11646–11651.

    PubMed  Article  CAS  Google Scholar 

  129. 129.

    Sarrazin C, Rouzier R, Wagner F, et al. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 132: 1270–1278.

    PubMed  Article  CAS  Google Scholar 

  130. 130.

    Sarrazin C and Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology, 138: 447–462.

    PubMed  Article  CAS  Google Scholar 

  131. 131.

    Scarselli E, Ansuini H, Cerino R, et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J, 21: 5017–5025.

    PubMed  Article  CAS  Google Scholar 

  132. 132.

    Seiwert S D, Andrews S W, Jiang Y, et al. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother, 52: 4432–4441.

    PubMed  Article  CAS  Google Scholar 

  133. 133.

    Shaw A N, Tedesco R, Bambal R, et al. 2009. Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. Bioorg Med Chem Lett, 19: 4350–4353.

    PubMed  Article  CAS  Google Scholar 

  134. 134.

    Sheaffer A K, Lee M S, Chaniewski S, et al. 2008. Resistance to a novel HCV replication inhibitor maps to amino acid changes within the NS4B Sequence. 15th International Symposium on Hepatitis C and Related Viruses, San Antonio, Texas.

  135. 135.

    Shi S T, Herlihy K J, Graham J P, et al. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother, 53: 2544–2552.

    PubMed  Article  CAS  Google Scholar 

  136. 136.

    Stankiewicz-Drogon A, Palchykovska L G, Kostina V G, et al. 2008. New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection. Bioorg Med Chem, 16: 8846–8852.

    PubMed  Article  CAS  Google Scholar 

  137. 137.

    Steinkuhler C, Biasiol G, Brunetti M, et al. 1998. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry, 37: 8899–8905.

    PubMed  Article  CAS  Google Scholar 

  138. 138.

    Steinmann E, Penin F, Kallis S, et al. 2007. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog, 3: e103.

    PubMed  Article  CAS  Google Scholar 

  139. 139.

    Steinmann E, Whitfield T, Kallis S, et al. 2007. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology, 46: 330–338.

    PubMed  Article  CAS  Google Scholar 

  140. 140.

    Taliani M, Bianchi E, Narjes F, et al. 1996. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem, 240: 60–67.

    PubMed  Article  CAS  Google Scholar 

  141. 141.

    Tellinghuisen T L, Marcotrigiano J, Rice C M. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature, 435: 374–379.

    PubMed  Article  CAS  Google Scholar 

  142. 142.

    Thibeault D, Maurice R, Pilote L, et al. 2001. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem, 276: 46678–46684.

    PubMed  Article  CAS  Google Scholar 

  143. 143.

    Tomei L, Failla C, Santolini E, et al. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol. 67: 4017–4026.

    PubMed  CAS  Google Scholar 

  144. 144.

    Ujjinamatada R K, Baier A, Borowski P, et al. 2007. An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2, 5-dihydro-1,3,5-triazin-2-yl) imidazole-1-beta-D-ribofura-noside. Bioorg Med Chem Lett, 17: 2285–2288.

    PubMed  Article  CAS  Google Scholar 

  145. 145.

    Vaillancourt F H, Pilote L, Cartier M, et al. 2009. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology, 387: 5–10.

    PubMed  Article  CAS  Google Scholar 

  146. 146.

    Wakita T, Pietschmann T, Kato T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med, 11: 791–796.

    PubMed  Article  CAS  Google Scholar 

  147. 147.

    Watashi K, Hijikata M, Hosaka M, et al. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38: 1282–1288.

    PubMed  Article  CAS  Google Scholar 

  148. 148.

    Watashi K, Ishii N, Hijikata M, et al. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell, 19: 111–122.

    PubMed  Article  CAS  Google Scholar 

  149. 149.

    Wedemeyer H, Schuller E, Schlaphoff V, et al. 2009. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine, 27: 5142–5151.

    PubMed  Article  CAS  Google Scholar 

  150. 150.

    Welbourn S, Green R, Gamache I, et al. 2005. Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J Biol Chem, 280: 29604–29611.

    PubMed  Article  CAS  Google Scholar 

  151. 151.

    Whitby K, Taylor D, Patel D, et al. 2004. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother, 15: 141–151.

    PubMed  CAS  Google Scholar 

  152. 152.

    Xiang A X, Webber S E, Kerr B M, et al. 2007. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids, 26: 635–640.

    PubMed  Article  CAS  Google Scholar 

  153. 153.

    Xue Q, Ding H, Liu M, et al. 2007. Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes. Arch Virol, 152: 955–962.

    PubMed  Article  CAS  Google Scholar 

  154. 154.

    Yang F, Robotham J M, Nelson H B, et al. 2008. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol, 82:5269–5278.

    PubMed  Article  CAS  Google Scholar 

  155. 155.

    Yang W, Zhao Y, Fabrycki J, et al. 2008. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob. Agents Chemother, 52: 2043–2052.

    PubMed  Article  CAS  Google Scholar 

  156. 156.

    Yi M, Villanueva R A, Thomas D L, et al. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA, 103: 2310–2315.

    PubMed  Article  CAS  Google Scholar 

  157. 157.

    Yoshida E, Kunimoto D, Lee S S, et al. 2006. Results of a phase 2 dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype 1 patients. Gastroenterology, 130: A784.

    Google Scholar 

  158. 158.

    Zeuzem S, Yoshida E M, Benhamou Y, et al. 2008. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology, 48: 407–417.

    PubMed  Article  CAS  Google Scholar 

  159. 159.

    Zhong J, Gastaminza P, Cheng G, et al. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA, 102: 9294–9299.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kai Lin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lin, K. Development of novel antiviral therapies for hepatitis C virus. Virol. Sin. 25, 246–266 (2010). https://doi.org/10.1007/s12250-010-3140-2

Download citation

Key words

  • HCV
  • Hepatitis
  • Antiviral
  • Polymerase
  • Cyclophilin